Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/182762
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response

AuthorsHerrero-Fernández, Inés; Pacheco, Yolanda M. CSIC ORCID; Genebat, Miguel; Rodríguez-Méndez, M. del Mar; Lozano-Domínguez, María del Carmen; Polaino, María José; Rosado-Sánchez, Isaac; Tarancón-Díez, Laura; Muñoz-Fernandez, M. Angeles; Ruiz-Mateos, Ezequiel; Leal, Manuel CSIC
KeywordsMaraviroc
Vaccine
HIV infection
Combined antiretroviral treatment
Hepatitis A virus
Hepatitis B virus
Issue DateJan-2018
PublisherAmerican Society for Microbiology
CitationAntimicrobial Agents and Chemotherapy 62(1): 02050-17 (2018)
AbstractThe response to the HBV vaccine in HIV-infected patients is deficient. Our aim was to analyze whether a suppressive combined antiretroviral treatment (cART) containing maraviroc (MVC-cART) was associated with a better response to HBV vaccine. Fifty-seven patients on suppressor cART were administered the HBV vaccine. The final response, the early response, and the maintenance of the response were assessed. An anti-HBs titer of >10 mIU/ml was considered a positive response. A subgroup of subjects was simultaneously vaccinated against hepatitis A virus (HAV). Lineal regression analyses were performed to determine demographic, clinical, and immunological factors associated with the anti-HBs titer. Vaccine response was achieved in 90% of the subjects. After 1 year, 81% maintained protective titers. Only simultaneous HAV vaccination was independently associated with the magnitude of the response in anti-HBs titers, with a P value of 0.045 and a regression coefficient (B) [95% confident interval (CI)] of 236 [5 to 468]. In subjects ≤50 years old (n = 42), MVC-cART was independently associated with the magnitude of the response (P = 0.009; B [95% CI], 297 [79 to 516]) together with previous vaccination and simultaneous HAV vaccination. High rates of HBV vaccine response can be achieved by revaccination, simultaneous HAV vaccination, and administration of cARTs including MVC. MVC may be considered for future vaccination protocols in patients on suppressive cART.
Publisher version (URL)https://doi.org/10.1128/AAC.02050-17
URIhttp://hdl.handle.net/10261/182762
DOI10.1128/AAC.02050-17
ISSN0066-4804
E-ISSN1098-6596
Appears in Collections:(IBIS) Artículos

Files in This Item:
File Description SizeFormat
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work

PubMed Central
Citations

2
checked on Jan 17, 2022

SCOPUSTM   
Citations

4
checked on Jan 18, 2022

WEB OF SCIENCETM
Citations

1
checked on Jan 18, 2022

Page view(s)

143
checked on Jan 20, 2022

Download(s)

27
checked on Jan 20, 2022

Google ScholarTM

Check

Altmetric

Dimensions


Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.